Prime Medicine Files 8-K with Corporate Updates

TL;DR

Prime Medicine filed an 8-K on 5/21 for 5/17 events - corporate docs & financials.

AI Summary

Prime Medicine, Inc. filed an 8-K on May 21, 2024, reporting events as of May 17, 2024. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws and includes financial statements and exhibits. The company is incorporated in Delaware and is in the biological products sector.

Why It Matters

This filing indicates potential changes in Prime Medicine's corporate structure or governance, which could impact its operational direction and shareholder rights.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any immediate negative financial or operational news.

Key Numbers

• 001-41536 — SEC File Number (Identifies the company's filing history with the SEC.)
• 84-3097762 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Prime Medicine, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• May 17, 2024 (date) — Date of earliest event reported
• May 21, 2024 (date) — Date of report
• 21 Erie Street Cambridge, MA 02139 (address) — Principal executive offices

FAQ

Filing Documents

• prme-20240517.htm (8-K) — 27KB
• a05-21x2024xamendedaoi.htm (EX-3.1) — 144KB
• 0001628280-24-024530.txt ( ) — 331KB
• prme-20240517.xsd (EX-101.SCH) — 2KB
• prme-20240517_lab.xml (EX-101.LAB) — 23KB
• prme-20240517_pre.xml (EX-101.PRE) — 13KB
• prme-20240517_htm.xml (XML) — 3KB

03 Amendments to Articles of Incorporation or Bylaws Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws Change in Fiscal Year. On May 17, 2024, in connection with its periodic review of corporate governance matters, including recent developments in Delaware case law, the Board of Directors (the "Board") of Prime Medicine, Inc. (the "Company") adopted and approved the Company's Second Amended and Restated Bylaws (the "Second A&R Bylaws"), effective immediately. The Second A&R Bylaws supersede and replace in their entirety the Company's Amended and Restated Bylaws in effect immediately prior to effectiveness of the Second A&R Bylaws. Among other things, the amendments set forth in the Second A&R Bylaws: (i) revise the procedures and disclosure requirements for advance notice of stockholder proposals and the nomination of candidates for election as directors, (ii) address the universal proxy rules adopted by the U.S. Securities and Exchange Commission, by clarifying that no person may solicit proxies in support of a director nominee other than the Board's nominees unless such person has complied with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, including applicable notice and solicitation requirements, (iii) clarify and update the procedures by which the Board conducts meetings including postponing, rescheduling or canceling stockholder meetings, and (iv) update and revise certain other routine, technical, and non-substantive provisions. The foregoing description of the updated provisions in the Second A&R Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Second A&R Bylaws, a copy of which is filed hereto as Exhibit 3.1 and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 3.1 Second Amended and Restated Bylaws of Prime Medicine, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 21, 2024 Prime Medicine, Inc. By: /s/ Keith Gottesdiener Name: Keith Gottesdiener, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR